India approves BPaLM regimen for 6-month MDR-TB treatment, aiming to eliminate TB by 2025.

India's Union Health Ministry has approved the BPaLM regimen for multi-drug resistant tuberculosis (MDR-TB) under its National TB Elimination Program. This new treatment, combining the drug Pretomanid with Bedaquiline and Linezolid, can cure MDR-TB in six months, significantly faster than the traditional 20-month regimen. The rollout aims to aid 75,000 patients and support India's goal to eliminate TB by 2025, ahead of global targets.

September 06, 2024
23 Articles